Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares
July 22, 2019 16:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., July 22, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public...
Forty Seven, Inc. Prices Underwritten Public Offering of 9,375,000 Shares of Common Stock
July 17, 2019 19:15 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., July 17, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten...
Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock
July 16, 2019 16:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public...
Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia
July 11, 2019 07:00 ET
|
Forty Seven, Inc.
-- Ono to Receive Exclusive License for All Therapeutic Uses of 5F9 in Select Asian Markets ---- Forty Seven to Receive up to $120M in Combined Upfront and Potential Development and Commercial...
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
June 15, 2019 09:00 ET
|
Forty Seven, Inc.
-- 5F9 Well-Tolerated in Combination with Rituximab ---- Durable Responses Observed in DLBCL and Indolent Lymphoma; Median Duration of Response Not Yet Reached ---- Overall Response Rate (ORR) of 36%...
Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
June 03, 2019 08:00 ET
|
Forty Seven, Inc.
-- 5F9 Well Tolerated with Clinical Activity as Monotherapy and in Combination with Azacitidine ---- CR Rate of 55% and ORR of 100% Observed in Patients with Higher-Risk MDS ---- CR/CRi Rate of 50%...
Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association
May 16, 2019 09:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer,...
Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting
May 15, 2019 17:01 ET
|
Forty Seven, Inc.
-- Forty Seven to Host Investor Event and Webcast on June 3, 2019 ---- Forty Seven Management to Participate in MATTER Panel, The Current and Future Wave of Immuno-Oncology Therapies, on May 30, 2019...
Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights
May 13, 2019 16:01 ET
|
Forty Seven, Inc.
-- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in r/r NHL to be Presented at EHA and ICML in June -- – Updated Data from Phase 1b Trial of 5F9 as Monotherapy and in...
Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma
May 10, 2019 08:01 ET
|
Forty Seven, Inc.
-- Plan to evaluate Forty Seven’s CD47 antibody in combination with rituximab and Calquence (acalabrutinib) -- -- Novel combination aims to leverage the macrophage component of the innate immune...